Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia

Key Inclusion Criteria:

• Subjects aged ≥ 18 years at screening;
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures;
• Able to provide written informed consent;
• ECOG performance status score of 0, 1, or 2;
• Patients with histologically or cytologically confirmed malignant solid tumor;
• Cancer cachexia documented in medical records;

Key Exclusion Criteria:

• History of hypersensitivity or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or molecules composed of monoclonal antibody components;
• Presence of reversible decreased food intake, as determined by the investigator;
• Receiving tube feeding or parenteral nutrition (total or partial parenteral nutrition) at screening;
• Severe gastrointestinal disorders (including esophagitis, gastritis, malabsorption);
• Cachexia caused by other reasons;
• Currently participating in another investigational drug study, or receipt of another investigational product ;